ImClone Appoints Kenneth J. Zuerblis Chief Financial Officer

NEW YORK--(Business Wire)--
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in
the development and commercialization of novel antibodies to treat
cancer, today announced that it has appointed Kenneth J. Zuerblis as
Senior Vice President and Chief Financial Officer, effective March 31,
2008.

Mr. Zuerblis, age 49, brings to ImClone more than 25 years of
financial and operational management experience. Mr. Zuerblis is best
known within the biotechnology industry as a former Chief Financial
Officer of Nasdaq-traded Enzon Pharmaceuticals, Inc., a
biopharmaceutical company focused on the treatment of cancer and other
life-threatening conditions. During his eleven-year tenure as Enzon's
Chief Financial Officer, the company successfully transitioned from a
small, royalty-based specialty pharmaceutical organization into a
fully integrated biopharmaceutical company with significant revenues
driven by five marketed products and substantial capabilities in
research, development, manufacturing, sales and marketing.

"Ken brings to ImClone a valuable combination of strategic,
financial, operational and public company experience as well as a
strong commitment to the development of new treatment options for
cancer," said John H. Johnson, Chief Executive Officer of ImClone. "He
has an impressive track record in growing a development-stage
organization into a profitable multi-product biopharmaceutical
company. We believe Ken will contribute substantially to ImClone's
efforts in becoming a fully-integrated global leader in cancer
therapies as we continue to aggressively pursue initiatives to
maximize our ERBITUX(R) franchise and further advance our robust
pipeline of novel antibodies."

Mr. Zuerblis joined Enzon in 1991 and served as its Chief
Financial Officer from 1994 to 2005. At Enzon, he oversaw all of the
company's finance, accounting and investor relations activities, as
well as information technologies and other operational areas. Notably,
during Mr. Zuerblis' tenure, Enzon expanded its proprietary pipeline,
established significant revenues from five marketed products, and
achieved profitability and positive cash flows.

"Joining ImClone at this stage in its transformation to a global
multi-product biopharmaceutical company is a tremendous opportunity,"
said Mr. Zuerblis. "I look forward to working with John and the team
to execute on our strategy to grow the company and build shareholder
value."

Prior to joining Enzon, Mr. Zuerblis was at KPMG LLP where he held
positions of increasing responsibility over a ten-year period, serving
in various advisory roles, including strategic business, tax, audit,
and debt and equity financings. Mr. Zuerblis is a certified public
accountant and has a degree in accounting from Seton Hall University.

About ImClone Systems

ImClone Systems Incorporated is a fully integrated
biopharmaceutical company committed to advancing oncology care by
developing and commercializing a portfolio of targeted biologic
treatments designed to address the medical needs of patients with a
variety of cancers. The Company's research and development programs
include growth factor blockers and angiogenesis inhibitors. ImClone
Systems' headquarters and research operations are located in New York
City, with additional administration and manufacturing facilities in
Branchburg, New Jersey. For more information about ImClone Systems,
please visit the Company's web site at http://www.imclone.com.

ERBITUX is a registered trademark of ImClone Systems Incorporated.

Certain matters discussed in this news release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 and the Federal securities
laws. Although the company believes that the expectations reflected in
such forward-looking statements are based upon reasonable assumptions
it can give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and
uncertainties that could cause actual results to differ materially
from those currently expected. Many of these factors are beyond the
company's ability to control or predict. Important factors that may
cause actual results to differ materially and could impact the company
and the statements contained in this news release can be found in the
company's filings with the Securities and Exchange Commission,
particularly those factors identified as "risk factors" in the
Company's most recent annual report of Form 10-K and in its quarterly
reports on Form 10-Q and current reports on Form 8-K. For
forward-looking statements in this news release, the company claims
the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995. The
company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.

ImClone Systems Incorporated
Tracy Henrikson, 908-243-9945
Corporate Communications
MEDIA@IMCLONE.COM
or
Rebecca Gregory, 646-638-5058
Corporate Communications

Copyright Business Wire 2008